PARTICIPATION AGREEMENT
COVER SHEET

*        *        *

OVERVIEW

The American Society of Clinical Oncology, Inc. (“ASCO”) is a non-profit professional oncology society committed to conquering cancer through research, education, and promotion of the highest-quality patient care. The Association of Community Cancer Centers (“ACCC”) is a non-profit organization dedicated to promoting the continuum of quality cancer care for individuals with cancer and the community. In furtherance of each organization’s missions, ASCO and ACCC are collaborating on efforts focused on ensuring that cancer clinical trials better reflect the diversity of cancer populations (the “Collaboration”). Through this collaboration, ASCO has developed a research site self-assessment tool to assess site structural and procedural factors that may impact patient screening and participation (the “Tool”), which ASCO is pilot testing with selected clinical trial sites (the “Tool Pilot Study”). ACCC has developed an implicit bias training program, with both didactic and interactive components, to educate clinical research and oncology care teams on the role biases play in clinical trial screening and enrollment (the “Training”), which ACCC is pilot testing with selected clinical trial sites (the “Training Pilot Study”), and collectively with the Tool Pilot Study, the “ASCO-ACCC Pilot Project”). Your oncology practice (the “Practice”) has expressed interest in participating in the ASCO-ACCC Pilot Project through the Tool Pilot Study and/or the Training Pilot Study, as further described in this Participation Agreement and in one or more Participation Election Forms, entered into from time to time, and incorporated herein.

This Participation Agreement, including any Participation Election Form(s), describes the roles and responsibilities of ASCO, ACCC, and your Practice for participating in the ASCO-ACCC Pilot Project. Please read these carefully.

Contact Information

Practice Name:
Practice Address:

Practice Research Administrator Contact
Name:
Title:
Phone:
Email:
PARTICIPATION AGREEMENT

1. ASCO-ACCC PILOT PROJECT PARTICIPATION

1.1 General The goal of the ASCO-ACCC Collaboration is to develop practical strategies to increase clinical trial participation of patients from racial and ethnic communities historically underrepresented in cancer treatment trials. The ASCO-ACCC Pilot Project is intended to develop and pilot test practical strategies geared toward clinical trial sites, to help improve their performance and increase screening and offering clinical trials to patients, with an initial focus on patients who are Black or Hispanic/Latinx. There are two specific objectives.

Objective 1: To develop and evaluate a site self-assessment tool that evaluates site enrollment performance and factors, such as procedures and programs, that affect who is screened for and offered cancer treatment trials.

Objective 2: To develop and evaluate an implicit bias training program which aims to acknowledge and/or mitigate implicit bias across research and care teams related to who is offered cancer clinical trials. The Training will feature two primary components – a curriculum-based program and an interventional exercise. During this pilot study, the Training will be delivered over the course of four (4) months with a total time commitment of 4-5 hours for participants.

1.2 Meetings. Practice must complete one mandatory orientation call prior to beginning the ASCO-ACCC Pilot Project. Practice will also have the opportunity, but not the obligation, to attend periodic training opportunities applicable to the Practice’s selected component(s) of the ASCO-ACCC Pilot Project, feedback opportunities, and other such meetings as applicable.

2. PARTIES’ OBLIGATIONS

2.1 Practice’s Obligations.

(a) Practice Research Administrator and Clinician Research Champion. Practice will designate a primary contact person (the “Practice Research Administrator”) and a clinician contact (the “Clinician Research Champion”). The Practice Research Administrator is responsible for coordinating the Practice’s completion of the ASCO-ACCC Pilot Project and is typically the Practice’s Research Administrator/Director. They will be expected to facilitate data collection at the
Practice and, if applicable, identify interested staff to complete the Training. The Clinician Research Champion is typically an investigator at the Practice who is committed to the ASCO-ACCC Pilot Project and increasing racial and ethnic diversity in cancer treatment trials. The Clinician Research Champion will be responsible for overseeing the Practice’s completion of the ASCO-ACCC Pilot Project. Practice may update their designated contacts by sending notice to the parties.

(b) Practice will participate in the ASCO-ACCC Pilot Project in accordance with this Agreement, the applicable Participation Election Form(s), the reasonable instructions of ASCO and ACCC, any directives, determinations, waivers, or approvals provided by ASCO to Practice from the institutional review board for the ASCO-ACCC Pilot Project designated by ASCO (the “IRB”), and all laws, rules, and regulations applicable to performance under this Agreement ("Applicable Law"), including but not limited to applicable statute, law, code, rule, regulation, or directive setting forth privacy, security, breach notification, or data protection requirements for personal data, personal information, personally identifiable information, sensitive personal data, or similar items (“Privacy Laws”).

(c) Practice will ensure that any employee, contractor, or agent performing or assisting with the performance of Practice’s obligations under this Agreement, including but not limited to the Practice Research Administrator and Clinician Research Champion (collectively, the “Practice Staff”) are appropriately qualified to perform their respective task(s). Practice will cause Practice Staff to comply with the terms of this Agreement, and will be responsible for any failure of Practice Staff to comply with the terms of this Agreement.

(d) Practice will ensure that the initial Site Interest Application, including the survey, statement of interest, and letter of support, is complete and accurate. Should any follow-up or additional information be required, the Practice will coordinate with ASCO and ACCC staff to complete the necessary work.

2.2 ASCO’s Obligations.

(a) Communication. ASCO will designate a primary contact person (the “ASCO-ACCC Pilot Project Contact”) who will be available to Practice for any inquiries about the ASCO-ACCC Pilot Project. The ASCO-ACCC Pilot Project Contact, or his or her designee, will also communicate with the Practice Research Administrator and the Clinician Research Champion regarding any questions or concerns about the ASCO-ACCC Pilot Project, to update contact information, and address any issues, questions, or concerns regarding the ASCO-ACCC Pilot Project.

(b) Participation Stipends. ASCO will pay a one-time stipend to Practice for the time and effort of Practice in participating under this Agreement. Such stipend will be paid in accordance with the terms contained in the applicable Participation Election Form. The Parties intend that any and all amounts to be paid to Practice under this Agreement represent the fair market value of the time and effort of Practice in performing under this Agreement to the best of their knowledge, and have not been determined in any manner that takes into account the volume or value of any referrals or business otherwise generated between the Parties.
Institutional Review Board. ASCO will obtain all necessary IRB review and oversight of the ASCO-ACCC Pilot Project. Subject to confidentiality provisions set forth in Section 4 of this Agreement, ASCO will provide to Practice the IRB determination letter.

2.3 ACCC’s Obligations.

(a) Communication. ACCC will designate a primary contact person (the “ACCC Contact”) who will be available to Practice for any inquiries about the ASCO-ACCC Pilot Project. The ACCC Contact, or his or her designee, will also communicate with the Practice Administrator regarding any questions or concerns about the ASCO-ACCC Pilot Project, to update contact information, and address any issues, questions, or concerns regarding the ASCO-ACCC Pilot Project.

(b) Coordination and Scheduling. ACCC will coordinate any convenings involving the Parties as related to the ASCO-ACCC Pilot Project. In addition, ACCC will work with the Practice Research Administrator, or his or her designee, for any scheduling and/or logistics. This may include orientation calls, 1:1 interviews, events, or other meetings.

3. DATA

3.1 Data. “Data” means all data submitted by Practice pursuant to this Participation Agreement through the Tool Pilot Study and/or the Training Pilot Study.

3.2 Practice represents and warrants that: (a) it has all necessary rights, authority, and permission to disclose and transmit Data, to ASCO and/or ACCC as required by this Participation Agreement, and to permit ASCO and/or ACCC to use the Data for purposes related to the ASCO-ACCC Pilot Project and the Collaboration; (b) the disclosure and transmission of Data as required by this Participation Agreement will not violate any agreement between Practice and a third party, Practice’s obligations to a third party, Practice’s policies or procedures, or any applicable federal, state, or local law, rule, regulation, guidance, or other requirement; and (c) Practice has obtained any and all patient and staff consents and authorizations as required by applicable laws and regulations or Practice’s internal policies to disclose the Data to ASCO and/or ACCC under this Participation Agreement and permit ASCO and/or ACCC to use the Data as contemplated hereby.

3.3 Intellectual Property. Subject to applicable laws, regulations, and the terms of this Participation Agreement, Practice hereby grants to both ASCO and ACCC a non-exclusive, perpetual, irrevocable, assignable, sublicensable, no-charge, royalty-free, worldwide license to use, prepare derivative works of, display, transmit, distribute, perform, sublicense, and reproduce any aggregated form of the Data and the derivative works. Any derivative works created by or on behalf of ASCO based on the Data, including, without limitation, analyses, excerpts, aggregate Data, compilations, summaries, publications, presentations, and reports as well as any and all feedback provided to ASCO and any and all software, database, forms, methodologies, algorithms, know-how, and any other items and information prepared, developed, collected, modified, compiled, or provided by or on behalf of ASCO (“ASCO Items”), and all intellectual property rights in the ASCO Items, including any improvements thereto, are owned solely by ASCO. Any derivative works created by or on behalf of ACCC based on the Data, including, without limitation, analyses, excerpts, aggregate Data, compilations, summaries, publications, presentations, and reports as well
as any and all feedback provided to ACCC and any and all software, database, forms, methodologies, algorithms, know-how, and any other items and information prepared, developed, collected, modified, compiled, or provided by or on behalf of ASCO ("ACCC Items"), and all intellectual property rights in the ACCC Items, including any improvements thereto, are owned solely by ACCC. Neither ASCO nor ACCC will use Practice’s Data for any purposes other than to aid in each organizations’ mission-based activities, to aid in the provision of membership services, and to support operational effectiveness and quality improvement activities, as determined by ASCO and/or ACCC.

3.4 **Use of Results by Practice.** Practice will only use the results of the ASCO-ACCC Pilot Project (the "Results") for Practice’s internal business purposes, and will not disclose any Results to any third party without the prior written consent of ASCO and ACCC.

4. **CONFIDENTIALITY**

4.1 **General.** “Confidential Information” means all information disclosed by or on behalf of one party (in such capacity, “Discloser”) to the other party (in such capacity, “Recipient”) that is marked or identified as confidential or proprietary or that would be understood by a reasonable person to be confidential or proprietary; provided, however, that Data is covered by the obligations under Section 3 and will not be deemed Confidential Information. Without limiting the generality of the foregoing, the Results, as well as any correspondence, determinations, approvals, waivers, or other materials from the IRB regarding the ASCO-ACCC Pilot Project will constitute ASCO’s Confidential Information.

4.2 **Exceptions.** Confidential Information does not include information which:

- is or becomes publicly available other than by a breach of this Agreement (or any action or inaction by a party’s employees, contractors, or other personnel (collectively, “Representatives”) that would, if done by the party, constitute a breach hereof), including without limitation any information filed with any governmental agency and therefore made available to the public;
- is disclosed to Recipient by a third party that is legally entitled to disclose such information without an obligation of confidentiality;
- Recipient can demonstrate by its written records was in Recipient’s possession free of any apparent obligation of nondisclosure or nonuse at the time it was communicated to Recipient by Discloser; or
- Recipient can demonstrate by its written records was developed by Recipient or its Representatives independently of and without reference to or use of any of Discloser’s Confidential Information.

**Use and Protection.** Each party, in its capacity as a Recipient, agrees:

- Not to disclose Discloser’s Confidential Information to any other person or entity;
- to use Discloser’s Confidential Information only for purposes of performing its obligations or exercising its rights under this Agreement;
- to disclose Discloser’s Confidential Information only to those of its Representatives who need to know such information for purposes of this Agreement and who are bound by
obligations with respect to such Confidential Information substantially similar to those set forth in this Agreement; and
to protect all of Discloser’s Confidential Information from unauthorized use, access, or disclosure in the same manner it protects its own confidential information of a similar nature, and in no event with less than a reasonable degree of care.
Due to the unique nature of the Confidential Information, the Parties agree that any breach or threatened breach of Section 4.4 may cause not only financial harm to Discloser, but also irreparable harm for which money damages may not be an adequate remedy.
Therefore, Discloser may be entitled, in addition to any other legal or equitable remedies, to seek an injunction or similar equitable relief against any such breach or threatened breach without the necessity of proving actual damages or posting any bond.

5. TERM AND TERMINATION

5.1 Term. This Participation Agreement will be effective as of the latest date signed by either party, and will continue through December 31, 2021, unless terminated by any Party as set forth in Section 5.2.

5.2 Early Termination. Any party may terminate this Participation Agreement, with or without cause, upon thirty (30) days’ prior written notice to the other parties.

5.3 Effect of Termination. In the event any party terminates this Participation Agreement, any executed Participation Election Forms shall also terminate.

6. INDEMNIFICATION. Practice agrees to indemnify, defend, and hold harmless ASCO, its officers, directors, trustees, employees, agents, independent contractors, subcontractors, and affiliates (collectively, the “ASCO Parties”), and ACCC, its officers, directors, trustees, employees, agents, independent contractors, subcontractors, and affiliates (collectively, the “ACCC Parties”) from and against any and all liabilities, damages, losses, claims, attorney fees, costs of litigation, or costs and expenses incident thereto (“Losses”), to the extent that such Losses arise from or are related to the Practice’s or the Practice’s directors’, trustees’, employees’ or agents’ negligent or willful acts or omissions, breach of the terms of this Participation Agreement (including, but not limited to, the Practice’s representation set forth in Section 3 above), or violation of any applicable law, to the extent permitted by law.

7. LIMITATION ON LIABILITY. NEITHER PRACTICE, ASCO, NOR ACCC WILL BE LIABLE FOR INDIRECT, CONSEQUENTIAL, OR INCIDENTAL DAMAGES (INCLUDING DAMAGES FOR LOSS OF PROFITS, REVENUE, DATA, OR USE) ARISING OUT OF THIS PARTICIPATION AGREEMENT, THE RESULTS, THE TOOL, THE TRAINING, TESTING OF THE TOOL, TESTING OF THE TRAINING, AND/OR ANY DISCLOSURES OF INFORMATION RECEIVED OR CREATED UNDER THIS PARTICIPATION AGREEMENT, WHETHER IN A LEGAL ACTION IN CONTRACT, OR TORT, EVEN IF THE APPLICABLE PARTY IS ON NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. THE PROVISIONS OF THIS SECTION SHALL SURVIVE TERMINATION OF THIS PARTICIPATION AGREEMENT.
8. **NO WARRANTY.** Neither ASCO nor ACCC make any warranty of any kind whatsoever, express or implied, including without limitation, any warranty or guarantee of results. Neither ASCO nor ACCC are responsible for the accuracy, completeness, and/or integrity of Practice’s Data, and ASCO and ACCC expressly disclaim any liability resulting from any such issues relating to such Data. ASCO provides the results of the Tool to Practice “as is”, and for quality improvement purposes only. The Tool’s results are not intended to direct clinical decision-making as to the care of individual patients of Practice, and do not constitute medical advice. ACCC provides the Training “as is”, and for Practice’s internal educational purposes only. The Training is not intended to direct clinical decision-making as to the care of individual patients of the Practice, and does not constitute medical advice. Practice represents and warrants that Practice and the clinicians affiliated with Practice are solely responsible for clinical decision-making and the exercise of sound medical judgment in the care and treatment of patients. Neither ASCO nor ACCC have any liability for clinical, operational, business, or any other decisions made by Practice on the basis of this program, the Tool, the Training, or any results.

9. **COMPLIANCE WITH LAWS.** Each of the parties represent and warrant that the collection, dissemination, and use of all data by such party will comply with all applicable laws and regulations, including, without limitation and to the extent applicable, HIPAA.

10. **INSURANCE.** Each party agrees to obtain and maintain, in full force and effect throughout the term of this Participation Agreement, such insurance coverage of a kind and in amounts that are commercially reasonable and customary for each party’s industry, size, and scope, and that are adequate to meet the party’s obligations under this Participation Agreement. Upon the other party’s request, each party will provide the other with a certificate of insurance as evidence of coverage.

11. **GENERAL PROVISIONS**

11.1 **Miscellaneous.** This Participation Agreement, including any selected Participation Election Form, shall constitute the entire understanding of the parties, and shall supersede all prior oral or written agreements with respect to the same subject matter. This Participation Agreement is not transferable or assignable by a party without the prior written consent of the other party, except that ASCO retains the right to assign this Participation Agreement to an ASCO affiliate. ASCO and/or ACCC may amend the terms of this Participation Agreement by providing prior written notice to Practice. Practice will be deemed to have indicated its consent to any changes provided in such written notice by continuing to participate in the ASCO-ACCC Pilot Project after receipt of written notice. If one or more provisions of this Participation Agreement are held to be unenforceable, they shall be excluded, and the remaining provisions enforced. Sections 3, 4, 5, 6.3, 7, 8, and this 12.1 of this Participation Agreement are intended to survive the termination or expiration of this Participation Agreement.

11.2 **Governing Law.** This Participation Agreement and all matters relating hereto is governed by the laws of the Commonwealth of Virginia without regard to conflict or choice of law principles. Any disputes concerning this Participation Agreement shall be subject to the exclusive jurisdiction of the federal and state courts serving the city of Alexandria, Virginia.

11.3 **Notices.** All notices under this Agreement shall be in writing and shall be effective when delivered by hand-delivery, or sent by United States registered or certified mail, postage
prepaid and return receipt requested, or consigned to an established overnight mail carrier, and addressed or delivered to the parties at the following addresses (or such other address as may hereafter be designated by the parties):

To ASCO:    American Society of Clinical Oncology, Inc.
            2318 Mill Road, Suite 800
            Alexandria, VA  22314
            Attn:  Chief Executive Officer

            A copy of any notice shall be sent to the attention of the Chief Operating Officer and General Counsel of ASCO at the same address.

To ACCC:    Association of Community Cancer Centers
            1801 Research Blvd, Suite 400
            Rockville, MD 20850
            Attn: Executive Director

To Practice:   ____________________________
                ______________________________
            Attn:  _______________________

11.4 Relationship of the Parties; Use of Name. The parties acknowledge that they are at all times acting and performing as independent contractors to, and not as agents, legal representatives, subsidiaries, joint ventures, partners, servants, or employees of, each other. No party will use the name, trademark, logos, symbols, or other images of the other party without the prior written approval of such party.

11.5 Authority. The persons executing this Participation Agreement represent and warrant that they have the full power and authority to enter into this Participation Agreement on behalf of the entities on whose behalf they are signing.

11.6 Counterparts. This Participation Agreement may be executed in one or more counterparts, any one of which need not contain the signatures of more than one party, but all such counterparts taken together will constitute one and the same instrument. Electronic signatures (whether digital or encrypted), signatures sent via facsimile or scanned into .PDF or similar format and transmitted via electronic mail, shall be deemed to constitute original signatures.
SIGNATURES

IN WITNESS WHEREOF, the parties have caused this Participation Agreement to be executed by their duly authorized representatives as of the last date executed below.

American Society of Clinical Oncology, Inc.  [PRACTICE]

By: ________________________________  By: ________________________________
Name: ________________________________  Name: ________________________________
Title: ________________________________  Title: ________________________________
Date: ________________________________  Date: ________________________________
PARTICIPATION AGREEMENT
PARTICIPATION ELECTION FORM

Practice wishes to participate in the following component(s) of the ASCO-ACCC Pilot Project:

- Tool Pilot Study, or
- Training Pilot Study, or
- Both the Tool and Training Pilot Studies

Practice must execute the applicable Participation Election Form(s) for each component in which Practice wishes to participate.
PARTICIPATION AGREEMENT
PARTICIPATION ELECTION FORM

Module: Tool Pilot Study

* * * *

1. General: Practice has agreed to participate in ASCO’s Tool Pilot Study by entering into a Participation Agreement with ASCO and ACCC (the “Participation Agreement”). This Participation Election Form is subject to, and expressly incorporated into, the Participation Agreement. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Participation Agreement. ASCO has developed this Tool to help cancer treatment trial sites assess their performance with enrolling patients from historically underrepresented racial and ethnic minority groups along the key stages of the clinical trial enrollment continuum. It will help sites identify structural, procedural, and other factors affecting participation and opportunities for performance and quality improvement. The Tool Pilot Study has an initial focus on patients who are Black or Hispanic/Latinx.

2. Tool Pilot Study:
   2.1. Practice Obligations. Practice will complete no later than September 30, 2021 the following as part of the Tool Pilot Study:
      2.1.1. Community and site profile information;
      2.1.2. Site self-assessment tool, which will include completion of questions to facilitate the following:
         2.1.2.1. Performance self-assessment; and
         2.1.2.2. Identification of opportunities for performance and quality improvement; and
      2.1.3. Feedback survey.
   2.2. ASCO Obligations. ASCO will complete the following as part of the Tool Pilot Study:
      2.2.1. Designation of a primary contact person (the “Tool Pilot Study Contact”) who will be available to Practice for any inquiries about the Tool Pilot Study. The Tool Pilot Study Contact, or his or her designee, will also communicate with the Practice Research Administrator and the Clinician Research Champion regarding any questions or concerns about the Tool Pilot Study, to follow up about the status of the Tool Pilot Study, to update contact information, and address any issues, questions, or concerns regarding the Tool Pilot Study;
      2.2.2. Provide Practice specific instructions and guidance regarding the completion of the Tool Pilot Study; and
      2.2.3. Payment of participation stipend as set forth in Section 4 of this Participation Election Form.

3. Reports: Following completion of the site self-assessment tool, Practice will receive an automatically generated report of its own performance assessment and opportunities for improvement.

4. Participation Stipend: In recognition of the time and effort of Practice in participating in the Tool Pilot Study, ASCO will provide Practice a one-time participation stipend. The stipend will be paid within sixty (60) days of Practice completing all requirements set forth in Section 2.1 of this Participation
Election Form. Should Practice choose to terminate the Agreement or its participation in the Tool Pilot Study prior to completion of requirements set forth in Section 2.1, ASCO will have no obligation to provide the applicable stipend or any portion thereof.

❖ SIGNATURES

Practice has caused this Participation Election Form to be executed by its duly authorized representative as of the last date executed below, and agrees to participate in the Tool Pilot Study on the foregoing terms. Upon signature and delivery to ASCO, this Participation Election Form shall be attached to Practice’s current Participation Agreement.

<table>
<thead>
<tr>
<th>Practice Name:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Signature:</td>
<td></td>
</tr>
<tr>
<td>Full Name:</td>
<td></td>
</tr>
<tr>
<td>Title:</td>
<td></td>
</tr>
<tr>
<td>Date:</td>
<td></td>
</tr>
</tbody>
</table>

ASCO:

AMERICAN SOCIETY OF CLINICAL ONCOLOGY, INC.

By: __________________________
Name: _________________________
Title: _________________________
Date: _________________________

ACCC:

ASSOCIATION OF COMMUNITY CANCER CENTERS

By: __________________________
Name: _________________________
Title: _________________________
Date: _________________________
PARTICIPATION AGREEMENT
PARTICIPATION ELECTION FORM

Module: Training Pilot Study

1. General: Practice has agreed to participate in ACCC’s Training Pilot Study by entering into a Participation Agreement with ASCO and ACCC (the “Participation Agreement”). This Participation Election Form is subject to, and expressly incorporated into, the Participation Agreement. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Participation Agreement. The Training Program is a curriculum-based program, combined with interventional exercises for enrolling patients, with an optional opportunity to meet with other participating sites virtually for an interactive discussion.

2. Training Pilot Study:
   2.1. Practice Obligations. Practice will complete the following as part of the Training Pilot Study:
      2.1.1. A demographic questionnaire for all participating staff;
      2.1.2. Implicit bias training program, which will include the following components:
             2.1.2.1. Completion of five (5) virtual learning modules;
             2.1.2.2. Participation in one (2) two-hour virtual workshop; and
             2.1.2.3. Possible participation in chart-stimulated recall interview and exercise (if randomly selected);
      2.1.3. Evaluation surveys (at time of virtual convening and 6-weeks post-convening).
   2.2. ACCC Obligations. ACCC will complete the following as part of the Training Pilot Study:
      2.2.1. ACCC will designate a primary contact person (the “Training Pilot Study Contact”) who will be available to Practice for any inquiries about the Training Pilot Study. The Training Pilot Study Contact, or his or her designee, will also communicate with the Practice Administrator regarding any questions or concerns about the Training Pilot Study.
      2.2.2. ACCC will coordinate and schedule all interviews and events as part of the Training Pilot Study.
   2.3. ASCO Obligations. ASCO will complete the following as part of the Training Pilot Study:
      2.3.1. Payment of participation stipend as set forth in Section 4 of this Participation Election Form.

3. Outputs: Following completion of the implicit bias training program, Practice will have access to the publicly available training content and facilitators guide to implement the training at their site, if desired.

4. Participation Stipend: In recognition of the time and effort of Practice in participating in the Training Pilot Study, ASCO will provide Practice a one-time participation stipend. The stipend will be paid within sixty (60) days of Practice completing all requirements set forth in Section 2.1 of this Participation Election Form. Should Practice choose to terminate the Agreement or its participation in the Training Pilot Study prior to completion of requirements set forth in Section 2.1, ASCO will have no obligation to provide the applicable stipend or any portion thereof.
SIGNATURES

Practice has caused this Participation Election Form to be executed by its duly authorized representative as of the last date executed below, and agrees to participate in the Training Pilot Study module on the foregoing terms. Upon signature and delivery to ASCO, this Participation Election Form shall be attached to Practice’s current Participation Agreement.

Practice Name: ____________________________
Signature: ________________________________
Full Name: ________________________________
Title: ____________________________________
Date: ________________________________

ASCO:

AMERICAN SOCIETY OF CLINICAL ONCOLOGY, INC.

By: ____________________________________
Name: ________________________________
Title: ________________________________
Date: ________________________________

ACCC:

ASSOCIATION OF COMMUNITY CANCER CENTERS

By: ____________________________________
Name: ________________________________
Title: ________________________________
Date: ________________________________